Fig. 4: Study design and comparison of the effects of intravenous versus subcutaneous administration of N6/αCD3-αCD28 on pharmacokinetics in naïve rhesus macaques. | Nature Communications

Fig. 4: Study design and comparison of the effects of intravenous versus subcutaneous administration of N6/αCD3-αCD28 on pharmacokinetics in naïve rhesus macaques.

From: Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections

Fig. 4

A Rhesus macaques (n = 3 per group) received a single dose of N6/αCD3-αCD28 either via intravenous or subcutaneous administration ranging at 20−100 ug kg−1 N6/αCD3-αCD28 delivered via either a single intravenous or subcutaneous injection at the dose ranging 20–100 ug kg−1. Lymph node and blood samples were collected at various timepoints before, during, and after the administration of N6/αCD3-αCD28. B Plasma levels and half-life of N6/αCD3-αCD28 were measured, as described in the “Materials and Method”. C, D Percentage trispecific N6/αCD3-αCD28 bound to CD4+ and CD8+ T cells in peripheral (C) and in lymph node (D). Trispecific N6/αCD3-αCD28 binding to T cells was determined using anti-human IgG4 (Southern Biotech) to measure the percentage of cells with bound N6/αCD3-αCD28 on the indicated subpopulations of T cells by flow cytometry. The data were plotted as the mean of three animals ±SEM. Source Data are provided as a Source Data file.

Back to article page